| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Apellis Pharmaceuticals, Inc. (APLS) has 17 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. APLS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 1.18M | $48.30M | - | |
| CEO | 482.0K | $19.78M | - | |
| Dir | 385.0K | $15.80M | - | |
| Dir | 161.6K | $6.63M | - | |
| CFO | 152.0K | $6.24M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Francois Cedric78 | Chief Executive Officer | Sell | 7,851 | $66.81 | $524,514.32 | -2.3% | -22.3% | -56.2% | |
| Jan 16, 2024 | Eisele Jeffrey76 | Chief Development Officer | Sell | 438 | $66.81 | $29,262.17 | -0.6% | -22.3% | -56.2% | |
| Jan 16, 2024 | Watson David O.70 | General Counsel | Sell | 4,240 | $66.81 | $283,268.46 | -3.7% | -22.3% | -56.2% | |
| Jan 16, 2024 | Deschatelets Pascal69 | Chief Scientific Officer | Sell | 1,632 | $66.81 | $109,031.64 | -0.1% | -22.3% | -56.2% | |
| Jan 16, 2024 | Townsend Adam J.74 | Chief Commercial Officer | Sell | 2,235 | $66.81 | $149,317.22 | -2.2% | -22.3% | -56.2% | |
| Jan 4, 2024 | Baumal Caroline69 | Chief Medical Officer | Sell | 2,751 | $60.05 | $165,206.90 | -7.7% | -6.2% | -44.9% | |
| Dec 27, 2023 | Eisele Jeffrey76 | Chief Development Officer | Sell | 303 | $59.70 | $18,088.59 | -0.3% | -6.3% | -47.6% | |
| Dec 19, 2023 | Watson David O.70 | General Counsel | Sale+OE | 3,905 | $57.23 | $223,471.79 | -2.1% | -3.0% | -41.3% | |
| Dec 1, 2023 | Dunlop A. Sinclair62 | Director | Sell | 24,000 | $61.14 | $1,467,240.00 | -11.1% | +0.6% | -44.9% | |
| Dec 1, 2023 | Scheibler Lukas54 | Chief Research Officer | Sale+OE | 10,000 | $60.00 | $600,000.00 | -12.8% | +0.6% | -44.9% |